Orasure Technologies (OSUR)
NASDAQ:OSUR
Top Page
Orasure Technologies
(NASDAQ:OSUR)
Select Model
Select Model
Rating:49Neutral
Price Target:
$3.00
▲(26.05% Upside)
Action:ReiteratedDate:03/31/26
The score is held down primarily by weakened financial performance (losses, steep revenue decline, and renewed cash burn). The latest earnings call provides some offset via strong cash/no-debt positioning and credible product/regulatory catalysts, while technicals are neutral and valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Strong cash position, zero debt
A large cash balance and no debt provide a durable financial runway to fund FDA submissions, near-term launches, and working capital while the company pursues its multi-year path to operating cash‑flow breakeven. This reduces refinancing risk and supports strategic optionality during recovery.
Negative Factors
Steep revenue decline and weakened profitability
A pronounced revenue contraction (multi-year decline from 2023) erased scale benefits and turned prior net margins positive into significant losses. Durable profitability depends on a meaningful top-line recovery; absent sustained demand, fixed costs and legacy scale inefficiencies will pressure returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash position, zero debt
A large cash balance and no debt provide a durable financial runway to fund FDA submissions, near-term launches, and working capital while the company pursues its multi-year path to operating cash‑flow breakeven. This reduces refinancing risk and supports strategic optionality during recovery.
Read all positive factors
Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$204.61M
Dividend YieldN/A
Average Volume (3M)771.42K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth-43.95%
EPS Growth-620.21%
CountryUS
Employees501
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.27
Shares Outstanding69,126,175
10 Day Avg. Volume735,713
30 Day Avg. Volume771,421
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue2.04
Enterprise Value/Gross Profit5.35
Enterprise Value/Ebitda-3.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$118.95M
Orasure Technologies Business Overview & Revenue Model
Company Description
OraSure Technologies, Inc. is a leader in the field of oral fluid diagnostics and medical devices, primarily focusing on the development and sale of products for the detection of infectious diseases and for drug testing. The company operates in tw...
How the Company Makes Money
OraSure makes money primarily by selling diagnostics and sample-collection products. Key revenue streams include: (1) Infectious disease diagnostics product sales: Revenue is generated from the sale of rapid and other diagnostic tests used to dete...
Orasure Technologies Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call highlights clear progress on strategic priorities: revenue slightly beat guidance midpoint, meaningful improvement in gross margins year-over-year, strong cash position with no debt, two significant FDA submissions targeting midyear launches, tangible international expansion (Canada launch, nearshoring in Africa) and early success integrating BiMedomics. Offsetting these positives are sizable operating losses and negative operating cash flow, a multi-year timeline to return to operating cash flow breakeven (target 2027), lingering funding-related headwinds in international public-health markets, regulatory timing uncertainty for new product launches, and under-utilized capacity that makes margin improvement contingent on revenue ramp. Overall, the call conveys cautious optimism grounded in a solid balance sheet and promising near-term product catalysts but tempered by execution risk and the need for top-line recovery to fully realize margin and cash-flow benefits.Positive Updates
Q4 Revenue Beat and Core Revenue
Total revenue of $26.8 million in Q4 2025; core revenue (ex-COVID) $26.7 million, above the midpoint of guidance.
Negative Updates
Operating Losses and Negative Operating Cash Flow
GAAP operating loss of $20.1 million and non-GAAP operating loss of $15.2 million in Q4 2025. Operating cash flow was negative $9 million in Q4; company expects to return to operating cash flow breakeven by 2027 (multi-year horizon).
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Revenue Beat and Core Revenue
Total revenue of $26.8 million in Q4 2025; core revenue (ex-COVID) $26.7 million, above the midpoint of guidance.
Read all positive updates
Company Guidance
The company guided Q1 revenue of $26 million to $29 million (negligible COVID revenue) and expects Q1 gross margin in the low‑40% range, a slight sequential improvement from Q4 2025 (GAAP gross margin 41.0%, non‑GAAP 41.4% vs. 36.2% and 40.1% in Q4 2024); Q4 revenue was $26.8 million (core $26.7M) with Diagnostic Products $15.1M and Sample Management Solutions $9.1M, R&D $11.4M, sales & marketing $6.6M, G&A $9.8M, noncash stock comp $1.5M, D&A $2.4M, GAAP operating loss $20.1M and non‑GAAP operating loss $15.2M. Balance sheet and cash management metrics include $199M cash and equivalents, zero debt, Q4 operating cash flow of negative $9M with a target to return to breakeven operating cash flow by 2027, $5M share repurchase (1.9M shares) in Q4 and $15M (5.3M shares) for all of 2025, and a ~$4M investment to acquire BiMedomics in Q4; management expects full‑year R&D to be lower with some continued clinical trial spend in Q1, is operating at roughly 30% capacity (so margins should improve with higher absorption), has completed ~95–97% of manufacturing consolidation to Bethlehem, and reiterated a midyear timeline for two product submissions with a revenue ramp anticipated in H2 2026.Orasure Technologies Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
40
Negative
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 115.02M | 185.83M | 405.47M | 387.48M | 233.67M |
| Gross Profit | 48.20M | 76.23M | 179.42M | 148.44M | 117.60M |
| EBITDA | -56.74M | -9.73M | 73.98M | 8.76M | 9.00K |
| Net Income | -68.73M | -19.50M | 53.66M | -17.13M | -23.00M |
Balance Sheet | |||||
| Total Assets | 403.17M | 479.66M | 482.85M | 444.18M | 460.99M |
| Cash, Cash Equivalents and Short-Term Investments | 199.28K | 267.76M | 290.41M | 110.85M | 153.04M |
| Total Debt | 13.20M | 14.60M | 13.50M | 12.55M | 12.27M |
| Total Liabilities | 62.34M | 69.32M | 52.17M | 79.75M | 80.46M |
| Stockholders Equity | 340.83M | 410.34M | 430.67M | 364.43M | 380.53M |
Cash Flow | |||||
| Free Cash Flow | -53.22K | 23.58M | 131.28M | -111.11M | -83.50M |
| Operating Cash Flow | -49.02K | 27.37M | 141.58M | -47.20M | -35.38M |
| Investing Cash Flow | -6.81K | -39.03M | 66.15M | 21.09M | -5.50M |
| Financing Cash Flow | -16.94K | -4.18M | -3.02M | -3.83M | -2.82M |
Orasure Technologies Technical Analysis
Positive
2.38
Price Trends
2.96
Positive
2.73
Positive
2.88
Positive
Market Momentum
0.02
Positive
53.84
Neutral
58.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Positive. The current price of 2.38 is below the 20-day moving average (MA) of 3.03, below the 50-day MA of 2.96, and below the 200-day MA of 2.88, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 53.84 is Neutral, neither overbought nor oversold. The STOCH value of 58.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSUR.
Orasure Technologies Risk Analysis
Orasure Technologies disclosed 66 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orasure Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $189.62M | 27.96 | 11.91% | ― | 6.23% | 283.88% | |
56 Neutral | $209.89M | 16.41 | 9.56% | 2.15% | -12.35% | -17.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $204.61M | -2.59 | -18.58% | ― | -43.95% | -620.21% | |
47 Neutral | $181.86M | -9.67 | -191.60% | ― | 19.61% | -3.42% | |
46 Neutral | $151.53M | -5.36 | -178.57% | ― | 30.55% | -340.19% |
* Healthcare Sector Average
OSUR
Orasure Technologies
3.08
0.15
5.12%
INFU
InfuSystem Holdings
9.73
4.70
93.44%
STXS
Stereotaxis
1.92
0.15
8.47%
UTMD
Utah Medical Products
67.15
15.21
29.28%
MBOT
Microbot Medical
2.35
-0.20
-7.84%
SMTI
Sanara MedTech
17.60
-11.78
-40.10%
Orasure Technologies Corporate Events
Business Operations and StrategyStock Buyback
OraSure Defends Strategy Amid Activist Altai Governance Challenge
Positive
Mar 30, 2026
On March 30, 2026, OraSure Technologies released a presentation defending its performance and governance in response to activist investor Altai Capital’s push to replace two independent directors, highlighting that its shareholder returns ha...
Executive/Board Changes
OraSure Technologies Announces Resignation of Board Member Shulkin
Neutral
Mar 5, 2026
On February 28, 2026, OraSure Technologies, Inc. announced that board member David J. Shulkin, M.D. had notified the company of his decision to resign as director and as a member of the Board’s Compensation Committee, effective March 2, 2026...
Business Operations and StrategyStock BuybackFinancial Disclosures
OraSure Highlights 2025 Results and 2026 Growth Outlook
Neutral
Feb 25, 2026
On February 25, 2026, OraSure reported fourth-quarter 2025 net revenue of $26.8 million, in line with expectations and above the midpoint of guidance, though down 29% year over year as total 2025 revenue fell 38% to $115.0 million, reflecting stee...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
OraSure Seeks FDA Clearance for New STI Tests
Positive
Jan 5, 2026
On January 5, 2026, OraSure Technologies reported that at the end of 2025 it submitted two applications to the U.S. Food and Drug Administration seeking clearance for a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.